Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
134
resultados
Última actualización
31/01/2026 [07:09:00]
Resumen de: WO2026020518A1
Disclosed is a disposable multi-dose high-precision insulin injection apparatus, comprising a housing, and a dose adjustment unit and an injection transmission unit that are arranged in the housing. The dose adjustment unit is arranged in the upper part in the housing, and the injection transmission unit is arranged in the lower part in the housing. A dose setting unit is in transmission connection with the injection transmission unit. The dose adjustment unit is used for presetting an injection dose, and the injection transmission unit is used for transmitting injection power and discharging the preset injection dose to complete an injection. The disposable multi-dose high-precision insulin injection apparatus described in the present invention uses the dose setting unit to set a dose of insulin to be injected and uses the injection transmission unit to complete the injection of the corresponding dose. The dose setting unit can accurately set a dose to be injected. The apparatus is simple and convenient to operate and cost-effective.
Resumen de: AU2026200109A1
There is disclosed a cap for an insulin pen comprising: one or more sensors adapted to detect a position of a plunger within an insulin pen; and a user interface comprising one or more user-selectable icons or buttons adapted to announce a meal or an intent to have a meal. have a meal. an a n h a v e a m e a l
Resumen de: US20260026758A1
A system for titrating a basal insulin dose that includes a glucose monitoring device configured to collect glucose data of a user, processors in communication with the glucose monitoring device, and a memory coupled to the processors. The processors are configured to determine an initial basal insulin dose, receive insulin data and glucose data during a titration period. The validity of each day is assessed, and a titration glucose level is determined for each valid day. The titration glucose level for each day is compared to glucose level thresholds, and a recommended adjustment to the basal insulin dose is determined based on the comparison.
Resumen de: US20260026749A1
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.
Resumen de: US20260027301A1
Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.
Resumen de: WO2026025081A1
A method for predicting a blood glucose or blood glucose condition in an individual. The method includes receiving, at a current time, data associated with the individual, the data including (i) a set of one or more static data points each being generated or collected at an identical prior point in time occurring before the current time, and (ii) a series of sequential data points, each of the sequential data points being generated or collected within a prior window of time occurring before the current time; inputting the data associated with the individual into a model; and receiving from the model an indication of a risk of the individual developing hypoglycemia within a subsequent window of time after the current time.
Resumen de: WO2026024081A1
According to one embodiment of the present disclosure, an electronic device may comprise: a substrate; a plurality of light sources disposed on the substrate and radiating light of different wavelengths; a temperature sensor disposed close to the plurality of light sources; a wavelength detection circuit electrically connected to at least two light sources among the plurality of light sources; a memory storing instructions; and a processor. The instructions, when executed by the processor, may cause the electronic device to acquire temperature information related to the plurality of light sources by using the temperature sensor. The instructions, when executed by the processor, may cause the electronic device to measure the amount of change in wavelength between the plurality of light sources by using the wavelength detection circuit. The instructions, when executed by the processor, may cause the electronic device to adjust the amount of change in wavelength to be less than or equal to a reference amount of change in wavelength when the amount of change in wavelength according to the acquired temperature information exceeds the reference amount of change in wavelength. The instructions, when executed by the processor, may cause the electronic device to supply a current corresponding to the adjusted amount of change in wavelength to the plurality of light sources. In addition to various embodiments disclosed in the present document, other various embodiments may be possible.
Resumen de: WO2026025065A2
A system for titrating a basal insulin dose that includes a glucose monitoring device configured to collect glucose data of a user, processors in communication with the glucose monitoring device, and a memory coupled to the processors. The processors are configured to determine an initial basal insulin dose, receive insulin data and glucose data during a titration period. The validity of each day is assessed, and a titration glucose level is determined for each valid day. The titration glucose level for each day is compared to glucose level thresholds, and a recommended adjustment to the basal insulin dose is determined based on the comparison.
Resumen de: WO2026024763A1
The system can include: an array of magnets. In variants, the system can function to generate a homogenous magnetic field within a sample (e.g., in the pulp of a finger). In an example, the system can be used for nuclear magnetic resonance (NMR) imaging and/or magnetic resonance imaging (MRI). In a specific example, the system can be used to measure blood analyte levels (e.g., glucose levels) within a sample.
Resumen de: WO2026023864A1
In an electronic device and an operation method of the electronic device, according to one embodiment, the electronic device may comprise: a light source unit for generating lights of a plurality of wavelength bands; an optical body for irradiating the lights of the plurality of wavelength bands onto the skin of a user; a light-receiving unit for detecting light obtained by reflecting the lights of the plurality of wavelength bands from the skin of the user; a memory for storing at least one computer program including instructions; and at least one processor. When individually or collectively executed by the at least one processor, the instructions can instruct the electronic device to: acquire the intensity of irradiation light of a specific wavelength band irradiated from the light source unit at the user and the intensity of reflected light obtained by reflecting the irradiation light of the specific wavelength band from the user; calculate the response gain of the irradiation light of the specific wavelength band on the basis of the ratio of the intensity of the irradiation light to the intensity of the reflected light; and identify a blood glucose level corresponding to the calculated response gain by using a blood glucose level database including blood glucose level information corresponding to the response gain of each of irradiation lights of the plurality of wavelength bands.
Resumen de: EP4685812A2
Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state.
Resumen de: US20260023141A1
The system can include: an array of magnets. In variants, the system can function to generate a homogenous magnetic field within a sample (e.g., in the pulp of a finger). In an example, the system can be used for nuclear magnetic resonance (NMR) imaging and/or magnetic resonance imaging (MRI). In a specific example, the system can be used to measure blood analyte levels (e.g., glucose levels) within a sample.
Resumen de: US20260024646A1
Disclosed herein are techniques related to product consumption recommendations. In some embodiments, the techniques may involve obtaining, for a patient, historical data comprising activity data, food consumption data, and glucose data. The techniques may further involve training a machine learning model to: predict glucose response parameters for the patient using the historical data as a training set; and utilize the predicted glucose response parameters to determine a recommendation associated with consumption of a product by the patient to maintain a glucose level within a target range during an activity.
Resumen de: US20260020780A1
Certain aspects of the present disclosure provide systems and techniques for rapid detection of repetitive metabolic events in a host based on measured analyte data provided by an analyte monitor worn by the host. An example system is configured to obtain measured glucose data of the host. A subset of the measured glucose data is determined, based on performing a filtering operation on the measured glucose data. A respective range of a likelihood of an occurrence of a metabolic is determined for each value within the subset of the measured glucose data. For at least one value within the subset of the measured glucose data, a state of the metabolic event is determined based in part on at least one of an upper bound or a lower bound of the respective range corresponding to the at least one value within the subset of the measured glucose data.
Resumen de: US20260020779A1
The present disclosure relates to a method for manufacturing an insertion guide needle for a continuous blood glucose monitoring device. The present disclosure provides a method for manufacturing an insertion guide needle for a continuous blood glucose monitoring device, by which: an insertion guide needle can be manufactured through a cutting process and a bending process of a needle raw plate, so that a complicated manufacturing process is unnecessary, and can thus be easily manufactured through a simple process; an enlargement incision part for continuous enlargement and incision, etc. can be conveniently manufactured through such a simple processing process, so that a manufacturing cost thereof can be reduced and also the size accuracy of the insertion guide needle can be improved; and, particularly, in a process of inserting the insertion guide needle into skin, the insertion guide needle can be brought into point contact with the skin to cut the skin, and then can continuously cut the skin in an enlarged manner, so as to minimize pains which may occur in the process of inserting the insertion guide needle into the skin, thereby alleviating the sense of repulsion or tension at the time of using the continuous blood glucose monitoring device.
Resumen de: US20260020785A1
The present disclosure relates to a continuous blood glucose measurement body attachment unit, and provides a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator so as to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip so as to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be more accurately measured.
Resumen de: US20260020784A1
Simulating a user's metabolic system and predicting a blood glucose response based on a specified food intake event includes receiving characteristic data representative of specified user characteristics, converting said characteristic data into object data and utilising said object data and a master model to generate a personal digital model representative of said user's metabolic system, receiving food intake data representative of a said specified food intake event, obtaining or generating current glucose data for said user, inputting said food intake data to said personal digital model, and generating, using said personal digital model, a simulation of said user's metabolic system in response to said food intake data and generating a predicted blood glucose response to said specified food intake event, outputting data representative of said predicted blood glucose response, and utilising said data representative of said predicted blood glucose response to retrain said master model and said personal digital model.
Resumen de: US20260021185A1
An improved local anesthetic solution with diminished bitter taste includes an anesthetic agent, an anesthetic solution vehicle, and a bitterness suppressant. The bitterness suppressant includes one or more compounds selected from the group consisting of: a sugar selected from the group consisting of monosaccharide sugars, disaccharide sugars, polysaccharide sugars, and combinations of the any of the foregoing; sweet-tasting compounds; acids; amino acids; salts; miscellaneous suppressant substances; and combinations of any of the foregoing. The improved local anesthetic solution optionally includes one or more additional agents selected from the group consisting of: buffering agents; vasoconstrictors; preservative compounds; stabilizers; contrast media agents; and combinations of any of the foregoing.
Resumen de: AU2024280120A1
Blood glucose level measurement includes a light source configured to irradiate light to a subject; a monochrome part configured to separate wavelength components of the light that is reflected and scattered from the subject; a light receiver configured to receive the light transmitted via the monochrome part and to generate electrical signals based on the received light; and a processor configured to extract information on the blood glucose level of the subject based on a frequency shift of the light due to the Raman effect.
Resumen de: AU2024335431A1
The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.
Resumen de: US20260021256A1
One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.
Resumen de: US20260022182A1
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Resumen de: US20260022183A1
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Resumen de: AU2024343861A1
A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure a ketone level in the bodily fluid of a patient. The application is configured to display at least one of (1) a current ketone level and an indicator of a current ketone trend, (2) a ketone trend graph, and (3) a total amount of time that the ketone levels are above at least one predetermined threshold level. The application is also configured to determine if the current ketone level is above the at least one predetermined threshold level, and in response to determining that the current ketone level is above the at least one predetermined threshold level, output an alarm, wherein the alarm is outputted periodically while the current ketone level is above the at least one predetermined threshold level.
Nº publicación: AU2024343617A1 22/01/2026
Solicitante:
UNIV OF VIRGINIA PATENT FOUNDATION
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Resumen de: WO2025064417A1
Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G'(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G'(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
BOPI
Sede Electrónica
